Development of immuno-oncology drugs-from CTLA4 to PD1 to the next generations

Nature Reviews Drug Discovery

Volumn 15, Issue 4, 2016, Pages 235-247

  Hoos, Axel ^a  

^a GLAXOSMITHKLINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTINEOPLASTIC AGENT; BIOLOGICAL MARKER; CYTOTOXIC T LYMPHOCYTE ANTIGEN 4; IMMUNOMODULATING AGENT; IPILIMUMAB; PROGRAMMED DEATH 1 RECEPTOR; SIPULEUCEL T; TICILIMUMAB; MONOCLONAL ANTIBODY;

ADAPTIVE IMMUNITY; ADVANCED CANCER; CANCER IMMUNOTHERAPY; CANCER SURVIVAL; CELLULAR IMMUNITY; CLINICAL PRACTICE; DRUG EFFICACY; DRUG SYNTHESIS; DRUG TREATMENT FAILURE; HUMAN; IMMUNOLOGY; IMMUNOMODULATION; INNATE IMMUNITY; MEDICAL RESEARCH; MELANOMA; NONHUMAN; ONCOLOGY; PRACTICE GUIDELINE; PRIORITY JOURNAL; REVIEW; RISK BENEFIT ANALYSIS; TREATMENT RESPONSE; DRUG EFFECTS; IMMUNITY; IMMUNOTHERAPY; MEDICATION THERAPY MANAGEMENT; NEOPLASMS; PROCEDURES; TREATMENT OUTCOME; TRENDS;

ANTIBODIES, MONOCLONAL; ANTINEOPLASTIC AGENTS; CTLA-4 ANTIGEN; HUMANS; IMMUNITY; IMMUNOTHERAPY; MEDICATION THERAPY MANAGEMENT; NEOPLASMS; PROGRAMMED CELL DEATH 1 RECEPTOR; TREATMENT OUTCOME;

EID: 84960366855     PISSN: 14741776     EISSN: 14741784     Source Type: Journal    
DOI: 10.1038/nrd.2015.35     Document Type: Review

References (129)

1. Balkwill, F. & Mantovani, A. Inflammation and cancer: Back to Virchow? Lancet 357, 539-545 (2001).
2. Coley, W. B. Contribution to the knowledge of sarcoma. Ann. Surg. 14, 199-220 (1891).
3. Koehler, G. & Milstein, C. Continuous cultures of fused cells secreting antibody of predefined specificity. Nature 256, 495-497 (1975).
4. Atkins, M. B. et al. High-dose recombinant interleukin 2 therapy for patients with metastatic melanoma: Analysis of 270 patients treated between 1985 and 1993. J. Clin. Oncol. 17, 2105-2116 (1999).
5. Kirkwood, J. M. et al. High- and low-dose interferon alfa-2b in high-risk melanoma: First analysis of intergroup trial E1690/S9111/C9190. J. Clin. Oncol. 18, 2444-2458 (2000).
6. Rosenberg, S. A., Yang, J. C. & Restifo, N. P. Cancer immunotherapy: Moving beyond current vaccines. Nat. Med. 10, 909-915 (2004).
7. Narang, A. S., Desai, D. in: Pharmaceutical Perspectives of Cancer Therapeutics (Eds Lu, Y. & Mahato, R. I.) 49-92 (Springer, 2009).
8. Sharma, P. & Allison, J. P. Immune checkpoint targeting in cancer therapy: Toward combination strategies with curative potential. Cell 161, 205-214 (2015).
9. Brunet, J. F. et al. A new member of the immunoglobulin superfamily - CTLA-4. Nature 328, 267-270 (1987).
10. Walunas, T. L. et al. CTLA-4 can function as a negative regulator of T cell activation. Immunity 1, 405-413 (1994).
11. Krummel, M. F. & Allison, J. P. CD28 and CTLA-4 have opposing effects on the response of T cells to stimulation. J. Exp. Med. 182, 459-465 (1995).
12. Leach, D. R., Krummel, M. F. & Allison, J. P. Enhancement of antitumor immunity by CTLA-4 blockade. Science 271, 1734-1736 (1996).
13. Keir, M. E., Butte, M. J., Freeman, G. J. & Sharpe, A. H. PD-1 and its ligands in tolerance and immunity. Annu. Rev. Immunol. 26, 677-704 (2008).
14. Mellman, I., Coukos, G. & Dranoff, G. Cancer immunotherapy comes of age. Nature 480, 480-489 (2011).
15. Pardoll, D. M. The blockade of immune checkpoints in cancer immunotherapy. Nat. Rev. Cancer 12, 252-264 (2012).
16. Topalian, S. L., Drake, C. G. & Pardoll, D. M. Immune checkpoint blockade: A common denominator approach to cancer therapy. Cancer Cell 27, 450-461 (2015).
17. Hoos, A. et al. A clinical development paradigm for cancer vaccines and related biologics. J. Immunother. 30, 1-15 (2007).
18. Hoos, A. et al. Development of ipilimumab: Contribution to a new paradigm for cancer immunotherapy. Semin. Oncol. 37, 533-546 (2010).
19. Weber, J. S. et al. Phase I/II study of ipilimumab for patients with metastatic melanoma. J. Clin. Oncol. 26, 5950-5956 (2008).
20. O'Day, S. J. et al. Efficacy and safety of ipilimumab monotherapy in patients with pretreated advanced melanoma: A multicenter single-arm Phase II study. Ann. Oncol. 21, 1712-1717 (2010).
21. Hoos, A., Britten, C. M., Huber, C. & O'Donnell- Tormey, J. A. Methodological framework to enhance the clinical success of cancer immunotherapy. Nat. Biotechnol. 29, 867-870 (2011).
22. Wolchok, J. D. et al. Guidelines for the evaluation of immune therapy activity in solid tumors: Immune-related response criteria. Clin. Cancer Res. 15, 7412-7420 (2009).
23. Finke, L. H. et al. Lessons from randomized Phase III studies with active cancer immunotherapies - outcomes from the 2006 meeting of the Cancer Vaccine Consortium (CVC). Vaccine 25, B97-B109 (2007).
24. Hoos, A. et al. Improved endpoints for cancer immunotherapy trials. J. Natl Cancer Inst. 102, 1388-1397 (2010).
25. Weber, J. S., Kähler, K. C. & Hauschild, A. Management of immune-related adverse events and kinetics of response with ipilimumab. J. Clin. Oncol. 30, 2691-2697 (2012).
26. Fecher, L. A., Agarwala, S. S., Hodi, F. S. & Weber, J. S. Ipilimumab and its toxicities: A multidisciplinary approach. Oncologist 18, 733-743 (2013).
27. Brahmer, J. R. et al. Safety and activity of anti-PD-L1 antibody in patients with advanced cancer. N. Engl. J. Med. 366, 2455-2465 (2012).
28. Hamid, O. et al. Safety and tumor responses with lambrolizumab (anti-PD-1) in melanoma. N. Engl. J. Med. 369, 134-144 (2013).
29. Andtbacka, R. H. et al. Talimogene laherparepvec improves durable response rate in patients with advanced melanoma. J. Clin. Oncol. 33, 2780-2788 (2015).
30. Hoos, A. & Britten, C. The immuno-oncology framework: Enabling a new era of cancer therapy. Oncoimmunology 1, 334-339 (2012).
31. US Department of Health and Human Services, Guidance for industry: Clinical considerations for therapeutic cancer vaccines. US Food And Drug Administration [online], http://www.fda.gov/downloads/biologicsbloodvaccines/guidancecomplianceregulatoryinformation/guidances/vaccines/ucm278673.pdf (2011).
32. EMA. Guideline on the evaluation of anticancer medicinal products in man (EMA/CHMP/205/95/Rev.4). European Medicines Agency [online], http://www.ema.europa.eu/docs/en-GB/document-library/Scientific-guideline/2013/01/WC500137128.pdf (2012).
33. Maio, M. et al. Five-year survival rates for treatment-naive patients with advanced melanoma who received ipilimumab plus dacarbazine in a phase III trial. J. Clin. Oncol. 33, 1191-1196 (2015).
34. Schadendorf, D. et al. Pooled analysis of long-term survival data from Phase II and Phase III trials of ipilimumab in unresectable or metastatic melanoma. J. Clin. Oncol. 33, 1889-1894 (2015).
35. Couzin-Frankel, J. Cancer Immunotherapy. Science 342, 1432-1433 (2013).
36. Baum, A. S. Immunotherapy - the beginning of the end for cancer. Citibank https://www.citivelocity.com/citigps/OpArticleDetail.action?recordId=209 (2013).
37. Hodi, F. S. et al. Improved survival with ipilimumab in patients with metastatic melanoma. N. Engl. J. Med. 363, 711-723 (2010).
38. Kantoff, P. W. et al. Sipuleucel-T immunotherapy for castration-resistant prostate cancer. N. Engl. J. Med. 363, 411-422 (2010).
39. Poole, R. M. Pembrolizumab: First global approval. Drugs 74, 1973-1981 (2014).
40. Topp, M. S. et al. Targeted therapy with the T-cell-engaging antibody blinatumomab of chemotherapy-refractory minimal residual disease in B-lineage acute lymphoblastic leukemia patients results in high response rate and prolonged leukemia-free survival. J. Clin. Oncol. 29, 2493-2498 (2011).
41. Topp, M. S. et al. Phase II trial of the anti-CD19 bispecific T cell-engager blinatumomab shows hematologic and molecular remissions in patients with relapsed or refractory B-precursor acute lymphoblastic leukemia. J. Clin. Oncol. 32, 4134-4140 (2014).
42. Topp, M. S. et al. Safety and activity of blinatumomab for adult patients with relapsed or refractory B-precursor acute lymphoblastic leukaemia: A multicentre, single-arm, Phase 2 study. Lancet Oncol. 16, 57-66 (2014).
43. Porter, D. L., Levine, B. L., Kalos, M., Bagg, A. & June, C. H. Chimeric antigen receptor-modified T cells in chronic lymphoid leukemia. N. Engl. J. Med. 365, 725-733 (2011).
44. Maude, S. L. et al. Chimeric antigen receptor T cells for sustained remissions in leukemia. N. Engl. J. Med. 371, 1507-1517 (2014).
45. Robert, C. et al. Ipilimumab plus dacarbazine for previously untreated metastatic melanoma. N. Engl. J. Med. 364, 2517-2526 (2011).
46. Eggermont, A. M. et al. Adjuvant ipilimumab versus placebo after complete resection of high-risk stage III melanoma (EORTC 18071): A randomised, double-blind, Phase 3 trial. Lancet Oncol.16, 522-530 (2015).
47. Kwon, E. D., et al. Ipilimumab versus placebo after radiotherapy in patients with metastatic castration-resistant prostate cancer that had progressed after docetaxel chemotherapy (CA184-043): A multicentre, randomised, doubleblind, phase 3 trial. Lancet Oncol. 15, 700-712 (2014).
48. Robert, C. et al. Nivolumab in previously untreated melanoma without BRAF mutation. N. Engl. J. Med. 372, 320-330 (2015).
49. Weber, J. S. et al. Nivolumab versus chemotherapy in patients with advanced melanoma who progressed after anti-CTLA-4 treatment (CheckMate 037): A randomised, controlled, open-label, Phase 3 trial. Lancet Oncol. 16, 375-384 (2015).
50. Brahmer, J. et al. Nivolumab versus docetaxel in advanced squamous-cell non-small-cell lung cancer. N. Engl. J. Med. 373, 123-135 (2015).
51. Robert, C. et al. Pembrolizumab versus ipilimumab in advanced melanoma. N. Engl. J. Med. 372, 2521-2532 (2015).
52. Larkin, J. et al. Combined nivolumab and ipilimumab or monotherapy in untreated melanoma. N. Engl. J. Med. 373, 23-34 (2015).
53. Bracarda, S. et al. Immunologic checkpoints blockade in renal cell, prostate, and urothelial malignancies. Semin. Oncol. 42, 495-505 (2015).
54. Powles, T. et al. MPDL3280A (anti-PD-L1) treatment leads to clinical activity in metastatic bladder cancer. Nature. 515, 558-562 (2015).
55. Lipson, E. J. et al. Durable cancer regression off-treatment and effective reinduction therapy with an anti-PD-1 antibody. Clin. Cancer Res. 19, 462-468 (2013).
56. Le, D. T. et al. PD-1 blockade in tumors with mismatch-repair deficiency. N. Engl. J. Med. 372, 2509-2520 (2015).
57. Ansell, S. M. et al. PD-1 blockade with nivolumab in relapsed or refractory Hodgkin's lymphoma. N. Engl. J. Med. 372, 311-319 (2015).
58. Nabel, G. J. Designing tomorrow's vaccines. N. Engl. J. Med. 368, 551-560 (2013).
59. Henao-Restrepo, A. M. et al. Efficacy and effectiveness of an rVSV-vectored vaccine expressing Ebola surface glycoprotein: Interim results from the Guinea ring vaccination cluster-randomised trial. Lancet 386, 857-866 (2015).
60. Lanier, L. L. NKG2D receptor and its ligands in host defense. Cancer Immunol. Res. 3, 575-582 (2015).
61. Zhang, J., Basher, F. & Wu, J. D. NKG2D ligands in tumor immunity: Two sides of a coin. Front. Immunol. 6, 97 (2015).
62. Lee, S. & Margolin, K. Cytokines in cancer immunotherapy. Cancers 3, 3856-3893 (2011).
63. Zlotnik, A. & Yoshie, O. The chemokine superfamily revisited. Immunity 36, 705-712 (2012).
64. Restifo, N. P., Dudley, M. E. & Rosenberg, S. A. Adoptive immunotherapy for cancer: Harnessing the T cell response. Nat. Rev. Immunol. 12, 269-281 (2012).
65. Gill, S. Going viral: Chimeric antigen receptor T cell therapy for hematological malignancies. Immunol. Rev. 263, 68-89 (2015).
66. Rapoport, A. P. et al. NY-ESO-1-specific TCR-engineered T cells mediate sustained antigen-specific antitumor effects in myeloma. Nat. Med. 21, 914-921 (2015).
67. Melero, I. et al. Therapeutic vaccines for cancer: An overview of clinical trials. Nat. Rev. Clin. Oncol. 11, 509-524 (2014).
68. Melief, C. J., Van Hall, T., Arens, R., Ossendorp, F. & Van Der Burg, S. H. Therapeutic cancer vaccines. J. Clin. Invest. 27, 1-12 (2015).
69. Kontermann, R. E. & Brinkmann, U. Bispecific antibodies. Drug Discov. Today 20, 838-847 (2015).
70. Weidle, U. H., Kontermann, R. E. & Brinkmann, U. Tumor-antigen-binding bispecific antibodies for cancer treatment. Semin. Oncol. 41, 653-660 (2014).
71. Adams, J. L., Smothers, J. Srinivasan, R. & Hoos, A. Big opportunities for small molecules in immuno-oncology. Nat. Rev. Drug Discov. 14, 603-622 (2015).
72. Lichty, B. D., Breitbach, C. J., Stojdl, D. F. & Bell, J. C. Going viral with cancer immunotherapy. Nat. Rev. Cancer 14, 559-567 (2014).
73. Kaczanowska, S., Joseph, A. M. & Davila, E. TLR agonists: Our best frenemy in cancer immunotherapy. J. Leukocyte Biol. 93, 847-863 (2013).
74. Chen, D. S. & Mellman, I. Oncology meets immunology: The cancer-immunity cycle. Immunity 39, 1-10 (2013).
75. Goldman, B. & Defrancesco, L. The cancer vaccine roller coaster. Nat. Biotechnol. 27, 129-139 (2009).
76. Gubin, M. M. et al. Checkpoint blockade cancer immunotherapy targets tumour-specific mutant antigens. Nature 515, 577-581 (2014).
77. Linnemann, C. et al. Highthroughput epitope discovery reveals frequent recognition of neo-antigens by CD4+ T cells in human melanoma. Nat. Med. 21, 81-85 (2015).
78. Alexandrov, L. B. et al. Signatures of mutational processes in human cancer. Nature 500, 415-421 (2013).
79. Carreno, B. M. et al. Cancer immunotherapy. A dendritic cell vaccine increases the breadth and diversity of melanoma neoantigen-specific T cells. Science 348, 803-808 (2015).
80. Schumacher, T. A vaccine targeting mutant IDH1 induces antitumour immunity. Nature 512, 324-327 (2014).
81. Britten, C. M. et al. The regulatory landscape for actively personalized cancer immunotherapies. Nat. Biotechnol. 31, 880-882 (2013).
82. Zamarin, D. et al. Localized oncolytic virotherapy overcomes systemic tumor resistance to immune checkpoint blockade immunotherapy. Sci. Transl. Med. 6, 226ra32.(2014).
83. Linette, G. P. et al. Cardiovascular toxicity and titin cross-reactivity of affinity-enhanced T cells in myeloma and melanoma. Blood 122, 863-871 (2013).
84. Chen, T. T. Milestone survival: A potential intermediate endpoint for immune checkpoint inhibitors. J. Natl. Cancer Inst. 107, djv156 (2015).
85. Hoos, A., Wolchok, J. D., Humphrey, R. & Hodi, F. S. Immune-related response criteria - capturing clinical activity in immuno-oncology. Clin. Cancer Res. 21, 1-3 (2015).
86. Nishino, M. et al. Developing a common language for tumor response to immunotherapy: Immune-related response criteria using unidimensional measurements. J. Immunother. Cancer 19, 3936-3943 (2013).
87. Van Der Burg, S. H. et al. Harmonization of immune biomarker assays for clinical studies. Sci. Transl. Med. 3, 108ps44 (2011).
88. Janetzki, S. et al. Guidelines for the automated evaluation of Elispot assays. Nat. Protoc. 10, 1098-1115 (2015).
89. Britten, C. M. et al. T cell assays and MIATA: The essential minimum for maximum impact. Immunity 37, 1-2 (2012).
90. Chapman, P. B. et al. Improved survival with vemurafenib in melanoma with BRAF V600E mutation. N. Engl. J. Med. 364, 2507-2516 (2011).
91. Robert, C. et al. Improved overall survival in melanoma with combined dabrafenib and trametinib. N. Engl. J. Med. 372, 30-39 (2015).
92. Horn, L. et al. Clinical activity, safety and predictive biomarkers of the engineered antibody MPDL3280A (anti-PDL1) in non-small cell lung cancer (NSCLC): Update from a phase Ia study. J. Clin. Oncol. 33 (Suppl.), 8029 (2015).
93. Spira, A. I. et al. Efficacy, safety and predictive biomarker results from a randomized Phase II study comparing atezolizumab (MPDL3280A) versus docetaxel in 2L/3L NSCLC (POPLAR). J. Clin. Oncol. 33 (Suppl.), 8010 (2015).
94. Spigel, D. R. et al. A phase III study (CheckMate 017) of nivolumab (NIVO; anti-programmed death-1 [PD-1]) versus docetaxel (DOC) in previously treated advanced or metastatic squamous (SQ) cell non-small cell lung cancer (NSCLC). J. Clin. Oncol. 33 (Suppl.), 8009 (2015).
95. Paz-Ares, L. et al. Phase III, randomized trial (CheckMate 057) of nivolumab (NIVO) versus docetaxel (DOC) in advanced non-squamous cell (non-SQ) non-small cell lung cancer (NSCLC). J. Clin. Oncol. 33 (Suppl.), LBA109 (2015).
96. Herbst, R. S. et al. Predictive correlates of response to the anti-PD-L1 antibody MPDL3280A in cancer patients. Nature 515, 563-567 (2014).
97. Mlecnik, B. et al. Histopathologic-based prognostic factors of colorectal cancers are associated with the state of the local immune reaction. J. Clin. Oncol. 29, 610-618 (2011).
98. Angell, H. & Galon, J. From the immune contexture to the Immunoscore: The role of prognostic and predictive immune markers in cancer. Curr. Opin. Immunol. 25, 261-267 (2013).
99. Kroemer, G., Galluzzi, L., Kepp, O. & Zitvogel, L. Immunogenic cell death in cancer therapy. Annu. Rev. Immunol. 31, 51-72 (2013).
100. Ng Tang, D. et al. Increased frequency of ICOS+ CD4 T cells as a pharmacodynamic biomarker for anti-CTLA-4 therapy. Cancer Immunol. Res. 1, 229-234 (2013).
101. Di Giacomo, A. M. et al. Long-term survival and immunological parameters in metastatic melanoma patients who responded to ipilimumab 10 mg/kg within an expanded access programme. Cancer Immunol. Immunother. 62, 1021-1028 (2013).
102. Hannani, D. et al. Anticancer immunotherapy by CTLA-4 blockade: Obligatory contribution of IL-2 receptors and negative prognostic impact of soluble CD25. Cell Res. 25, 208-224 (2015).
103. Vanneman, M. & Dranoff, G. Combining immunotherapy and targeted therapies in cancer treatment. Nat. Rev. Cancer 12, 237-251 (2012).
104. Liu, L. et al. The BRAF and MEK inhibitors dabrafenib and trametinib: Effects on immune function and in combination with immunomodulatory antibodies targeting PD1, PD-L1 and CTLA-4. Clin. Cancer Res. 21, 1639-1651 (2015).
105. Wolchok, J. D. et al. Nivolumab plus ipilimumab in advanced melanoma. N. Engl. J. Med. 369, 122-133 (2013).
106. Lynch, T. J. et al. Ipilimumab in combination with paclitaxel and carboplatin as first-line treatment in stage IIIB/IV non-small-cell lung cancer: Results from a randomized, double-blind, multicenter Phase II study. J. Clin. Oncol. 30, 2046-2054 (2012).
107. Ribas, A., Hodi, F. S., Callahan, M., Konto, C. & Wolchok, J. Hepatotoxicity with combination of vemurafenib and ipilimumab. N. Engl. J. Med. 368, 1365-1366 (2013).
108. Minor, D. R., Puzanov, I., Callahan, M. K., Hug, B. A. & Hoos, A. Severe gastrointestinal toxicity with administration of trametinib in combination with dabrafenib and ipilimumab. Pigment Cell Melanoma Res. 28, 611-612 (2015).
109. Chen, S. et al. Combination of 4-1BB agonist and PD-1 antagonist promotes antitumor effector/memory CD8 T cells in a poorly immunogenic tumor model. Cancer Immunol. Res. 3, 149-160 (2015).
110. Woo, S. R. et al. Immune inhibitory molecules LAG-3 and PD-1 synergistically regulate T-cell function to promote tumoral immune escape. Cancer Res. 72, 917-927 (2012).
111. Guo, Z. et al. Combined TIM-3 blockade and CD137 activation affords the long-term protection in a murine model of ovarian cancer. J. Transl. Med. 11, 215 (2015).
112. Shin, D. S. & Ribas, A. The evolution of checkpoint blockade as a cancer therapy: What's here, what's next? Curr. Opin. Immunol. 33, 23-35 (2015).
113. Borghaei, H. et al. Nivolumab versus docetaxel in advanced nonsquamous non-small-cell lung cancer. N. Engl. J. Med. 373, 1627-1639 (2015).
114. Motzer, R. J. et al. Nivolumab versus everolimus in advanced renal cell carcinoma. N. Engl. J. Med. 373, 1803-1813 (2015).
115. Herbst, R. S. et al. Pembrolizumab versus docetaxel for previously treated, PD-L1-positive, advanced non-small-cell lung cancer (Keynote-010): A randomized controlled trial. Lancet http://dx.doi.org/10.1016/S0140-6736(15)01281-7 (2015).
116. Topalian, S. L. et al. Immunotherapy: The path to win the war on cancer? Cell 161, 185-186 (2015).
117. Eggermont, A. M., Maio, M. & Robert, C. Immune checkpoint inhibitors in melanoma provide the cornerstones for curative therapies. Semin. Oncol. 42, 429-435 (2015).
118. Hoos, A. Proposal of a clinical development paradigm for cancer immunotherapy: Novel endpoints. In: Endpoints for immunotherapy studies: Design and regulatory implications (poster presentation). American Society of Clinical Oncology (ASCO) Annual Meeting (2008).
119. Hoos, A. Evolution of end points for cancer immunotherapy trials. Ann. Oncol. 23 (Suppl 8), viii47-viii52 (2012).
120. Wolchok, J. D. et al. Ipilimumab monotherapy in patients with pretreated advanced melanoma: A randomised, double-blind, multicentre, phase 2, dose-ranging study. Lancet Oncol. 11, 155-164 (2010).
121. Bristol-Myers Squibb. Ipilimumab risk evaluation and mitigation strategy. US Food and Drug Administration [online], http://www.accessdata.fda.gov/drugsatfda-docs/rems/Yervoy-2012-02-16-Full.pdf (2011).
122. Topalian, S. L. et al. Safety, activity, and immune correlates of anti-PD-1 antibody in cancer. N. Engl. J. Med. 366, 2443-2454 (2012).
123. Ribas, A. et al. Phase III randomized clinical trial comparing tremelimumab with standard-of-care chemotherapy in patients with advanced melanoma. J. Clin. Oncol. 31, 616-622 (2013).
124. Ribas, A., Hauschild, A., Kefford, R., Punt, C. J. A. & Haanen, J. B. Phase III open-label, randomized, comparative study of tremelimumab (CP-675,206) and chemotherapy (temozolomide [TMZ] or dacarbazine [DTIC]) in patients with advanced melanoma. J. Clin. Oncol. 26 (Suppl.), LBA9011 (2008).
125. Schreiber, R. D., Old, L. J. & Smyth, M. J. Cancer immunoediting: Integrating immunity's roles in cancer suppression and promotion. Science. 331, 1565-1570 (2011).
126. Yuan, J. Correlation of clinical and immunological data in a metastatic melanoma patient with heterogeneous tumor responses to ipilimumab therapy. Cancer Immun. 10, 1 (2010).
127. Hodi, F. S. et al. Immunologic and clinical effects of antibody blockade of cytotoxic T-lymphocte antigen 4 in previously vaccinated cancer patients. Proc. Natl Acad. Sci. 105, 3005-3010 (2008).
128. Ribas, A., Chmielowski, B. & Glaspy, J. A. Do we need a different set of response assessment criteria for tumor immunotherapy? Clin. Cancer Res. 15, 7116-7118 (2009).
129. Merchant, M. S. et al. Genetically engineered NY-ESO-1 specific T cells in HLA-A201+ patients with advanced cancers. J. Clin. Oncol. (Meeting Abstracts) 33 (Suppl.), TPS3102 (2015).